Benzamide, 4-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-[8-(hydroxyamino)-8-oxooctyl]-

Request For Quotation
Benzamide, 4-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-[8-(hydroxyamino)-8-oxooctyl]- Suppliers list
Company Name: Shanghai Beckham Medical Technology Co., Ltd  
Tel: 13816613772
Email: huahero21@sina.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: TargetMol Chemicals Inc.  
Tel: 13564774135
Email: marketing@targetmol.com

Benzamide, 4-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-[8-(hydroxyamino)-8-oxooctyl]- manufacturers

  • HDAC/HSP90-IN-3
  • HDAC/HSP90-IN-3 pictures
  • $1980.00
  • 2026-05-11
  • CAS:2700035-54-5
  • Purity:
  • Supply Ability: 10g
Benzamide, 4-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-[8-(hydroxyamino)-8-oxooctyl]- Basic information
Product Name:Benzamide, 4-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-[8-(hydroxyamino)-8-oxooctyl]-
Synonyms:Benzamide, 4-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-[8-(hydroxyamino)-8-oxooctyl]-;HDAC/HSP90-IN-3
CAS:2700035-54-5
MF:C26H33N5O6
MW:511.57
EINECS:
Product Categories:
Mol File:2700035-54-5.mol
Benzamide, 4-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-[8-(hydroxyamino)-8-oxooctyl]- Structure
Benzamide, 4-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-[8-(hydroxyamino)-8-oxooctyl]- Chemical Properties
density 1.35±0.1 g/cm3(Predicted)
pka4.86±0.20(Predicted)
Safety Information
MSDS Information
Benzamide, 4-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-[8-(hydroxyamino)-8-oxooctyl]- Usage And Synthesis
UsesHDAC/HSP90-IN-3 (compound J5) is a potent and selective fungal Hsp90 and HDAC dual inhibitor, with IC50 values of 0.83 and 0.91 μM, respectively. HDAC/HSP90-IN-3 shows antifungal activity against azole resistant C. albicans. HDAC/HSP90-IN-3 can suppress important virulence factors and down-regulate drug-resistant genes ERG11 and CDR1[1].
IC 50HSP90: 0.83 μM (IC50, fungal Hsp90); HDAC: 0.91 μM (IC50, fungal HDACs); human HDAC: 3.0 μM (IC50, human HDACs); HSP90: 19.52 μM (IC50, human Hsp90)
References[1] Li C, Tu J, Han G, Liu N, Sheng C. Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans. Eur J Med Chem. 2022 Jan 5;227:113961. DOI:10.1016/j.ejmech.2021.113961
Benzamide, 4-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-[8-(hydroxyamino)-8-oxooctyl]- Preparation Products And Raw materials
Tag:Benzamide, 4-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-[8-(hydroxyamino)-8-oxooctyl]-(2700035-54-5) Related Product Information
Benzamide, 4-[3-[2,4-dihydroxy-5-(1-methylethyl)phenyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-N-[8-(hydroxyamino)-8-oxooctyl]- Rapamycin Nystatin 17-AAG SB 203580 5'-O-[(4-Cyanophenyl)methyl]-8-[[(3,4-dichlorophenyl)methyl]amino]-adenosine